Yuka Hayashizaki

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · European Journal of Pharmacology · 2013 · 310 citations

Medicine, Endocrinology, Pharmacology +17

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

Masanori Yokono, Toshiyuki Takasu, Yuka Hayashizaki et al. · European Journal of Pharmacology · 2014 · 194 citations · Full text

Life Sciences, Endocrinology, Pharmacology +10

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · Journal of Pharmacy and Pharmacology · 2014 · 125 citations

Medicine, Pharmacology, Pharmacotherapy +17

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2011 · 109 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats

Shoji Takakura, Tohru Toyoshi, Yuka Hayashizaki et al. · Life Sciences · 2016 · 67 citations

Medicine, Endocrinology, Pharmacology +15